Efficacy and Safety of ENERGI-F701 Solution Versus 2% Minoxidil Solution for Female Pattern Hair Loss: A Phase II, Multi-Center, Randomized, Double-Blind, Head-to-Head, Parallel Trial
April 2023
Related
6 / 6 results
research Efficacy and Safety of ENERGI-F701 Solution Versus 2% Minoxidil Solution for Female Pattern Hair Loss: A Phase II, Multi-Center, Randomized, Double-Blind, Head-to-Head, Parallel Trial
ENERGI-F701 solution was found to be more effective and safer than Regaine® 2% minoxidil solution in treating female pattern hair loss, with increased hair density and less side effects.
research Randomized Clinical Trial of Low-Dose Oral Minoxidil for the Treatment of Female Pattern Hair Loss: 0.25 mg Versus 1 mg
research Faculty Opinions Recommendation of Sublingual Minoxidil for the Treatment of Male and Female Pattern Hair Loss: A Randomized, Double-Blind, Placebo-Controlled, Phase 1B Clinical Trial
research Efficacy and Safety of a Novel Herbal Solution for the Treatment of Androgenetic Alopecia and Comparison with 5% Minoxidil: A Double-Blind, Randomized Controlled Trial Study
Herbal solution improves hair diameter and density more than 5% minoxidil for androgenetic alopecia.
research Efficacy and Safety of Topical Combination of 3% Minoxidil and 0.25% Finasteride Versus 3% Minoxidil Solution in Female-Pattern Hair Loss: A Randomized, Double-Blind, Controlled Study
Combination of minoxidil and finasteride is more effective in increasing hair diameter than minoxidil alone for female-pattern hair loss.
research Androgenetic Alopecia in the Female
2% topical minoxidil effectively treats female hair loss with minimal side effects.